More developments from the cannabis front Thursday.
Toronto-based Khiron Life Sciences Corp. (TSX-Venture: KHRN), a vertically integrated cannabis leader with core operations in Latin America and Europe, joined in an agreement with Nimbus Health, a leading German distributor of medical cannabis products. Khiron branded EU GMP medical cannabis will soon be available in Germany for prescription by doctors and dispensation in pharmacies.
Tejinder Virk, President of Khiron Europe, commented: “This is a major milestone for our company. Following our recent entry into the United Kingdom, the expansion into Germany will greatly benefit patients who still suffer from inconsistent supply. Khiron is now well positioned to service this rapidly expanding market in Germany.”
KHRN shares did not have the jump some stocks in this category sometimes enjoy, only two cents, or 3.7%, to 56 cents, though volume was a respectable 552,000 shares.